5445582025-10-012025-12-315445582025-12-315445582025-04-012025-12-315445582025-10-012025-12-31in-capmkt:OtherExpenses1Member5445582025-10-012025-12-31in-capmkt:OtherExpenses2Member5445582025-10-012025-12-31in-capmkt:OtherExpenses3Member5445582025-10-012025-12-31in-capmkt:OtherExpenses4Member5445582025-10-012025-12-31in-capmkt:OtherExpenses5Member5445582025-10-012025-12-31in-capmkt:OtherExpenses6Member5445582025-10-012025-12-31in-capmkt:OtherExpenses7Member5445582025-10-012025-12-31in-capmkt:OtherExpenses8Member5445582025-10-012025-12-31in-capmkt:OtherExpenses9Member5445582025-10-012025-12-31in-capmkt:OtherExpenses10Member5445582025-04-012025-12-31in-capmkt:OtherExpenses1Member5445582025-04-012025-12-31in-capmkt:OtherExpenses2Member5445582025-04-012025-12-31in-capmkt:OtherExpenses3Member5445582025-04-012025-12-31in-capmkt:OtherExpenses4Member5445582025-04-012025-12-31in-capmkt:OtherExpenses5Member5445582025-04-012025-12-31in-capmkt:OtherExpenses6Member5445582025-04-012025-12-31in-capmkt:OtherExpenses7Member5445582025-04-012025-12-31in-capmkt:OtherExpenses8Member5445582025-04-012025-12-31in-capmkt:OtherExpenses9Member5445582025-04-012025-12-31in-capmkt:OtherExpenses10Member5445582025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15445582025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15445582025-12-31Statement15445582025-10-012025-12-31Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares544558FABTECHNOTLISTEDINE0HF201011Fabtech Technologies LimitedMain BoardEquity2025-04-012026-03-312026-02-022026-01-28INRLakhsQuarterlyThird quarterSingle segmentBuilding pharmaceutical, biotech and healthcare capabilities for wide range of customers by offering comprehensive start to finish turnkey solutions, which includes supplying pharmaceutical machineries / equipment, in house designing engineering, procurement, installation, validation and to undertake other activities required in various projects including standalone equipment supply and installation2026-02-0216:43:002026-02-0217:00:00Not applicabletrue1falseThere are no such defaults.2025-10-012025-12-31UnauditedStandalone471579000767240005483030000334143000-58185000720750009065000122350001720400005413730006930000069300005405000-13353000-794800001487800000001487800050800015386000444508000100.410.41000.410.41Due to word limit Constraint, please refer notes in Outcome of Board Meeting Results tab.2025-04-012025-12-31UnauditedStandalone157850400012943500017079390000823841000-2246900019368400033693000376540004928150001559218000148721000905200015777300043005000-222840002072100001370520000000137052000-165000136887000444508000103.773.77003.773.77Business Promotion and Advertising50354000Project erection and commissioning expenses38353000Travelling and Conveyance expenses22247000Freight and forwarding20706000Legal and professional charges13661000Bank Charges1756000Provision for Doubtful Debt and advances11998000Communication expenses1397000Repairs and maintenance989000Miscellaneous expenses10579000Business Promotion and Advertising87800000Project erection and commissioning expenses159447000Travelling and Conveyance expenses60537000Freight and forwarding88029000Legal and professional charges26058000Bank Charges7011000Provision for Doubtful Debt and advances32653000Communication expenses4618000Repairs and maintenance3484000Miscellaneous expenses23178000Remeasurement of defined benefit plans679000679000Remeasurement of defined benefit plans-221000-221000171000-56000508000-165000Public Issues2025-10-0723029650002025-12-31trueCRISIL Ratings LimitedfalseAmjad Adam ArbaniDirectorMumbai2026-02-02